Tag Archives: take

JPM: Alexion to take Ultomiris into tough ALS study as switching campaign exceeds expectations

Alexion’s winning its campaign to switch patients from its blockbuster Soliris to next-gen follow-up Ultomiris. Not content to simply move patients over, though, the company’s taking a swing at a new Ultomiris indication where other candidates have struck out. The company will start a phase 3 trial for Ultomiris in amyotrophic lateral sclerosis (ALS), an indication… Read More »